Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: A prospective multicenter study in China

Journal of Infection and Chemotherapy

Volumn 15, Issue 5, 2009, Pages 301-311

  Zhang, Ying Yuan ^a   Huang, Hai Hui ^a   Ren, Zhen Yi ^b   Zheng, Hong Guang ^c   Yu, Yun Song ^d   Lü, Xiao Ju ^e   Xiao, Zu Ke ^f   Yang, Hui Fen ^g   Xiu, Qing Yu ^h   Chen, Bao Yuan ^g   Yue, Hong Mei ⁱ   Hao, Qing Lin ^j   Huang, Jian An ^k   Ma, Hui ^l   Xiao, Wei ^m   Guo, Dong Yang ⁿ   Si, Bin ^o   Sun, Sheng Hua ^p   Zhang, Wei ^q   Li, Qi Hao ^j   Shen, Hua Hao ^d   Duan, Jian ^r   Li, Hua Yin ^s   Yao, Wan Zhen ^t   Gu, Jun Ming ^u   Xia, Qian Ming ⁿ   Ying, Ke Jing ^v   Liu, Ao ^r   Yang, He Ping ^w   Shi, Min Hua ^k   Sun, Tie Ying ^x   Ding, Guo Hua ^y   Wu, Guo Ming ^w   more..

^a FUDAN UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

^f People's Hospital of Jiangxi Province   (China)

^g TIANJIN MEDICAL UNIVERSITY   (China)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

ⁱ LANZHOU UNIVERSITY   (China)

^j KUNMING MEDICAL UNIVERSITY   (China)

^k SUZHOU UNIVERSITY   (China)

^l GANSU PROVINCIAL HOSPITAL   (China)

^m SHANDONG UNIVERSITY   (China)

ⁿ General Hospital of the Chengdu Military Command   (China)

^o General Hospital of Wuhan Military   (China)

^p CENTRAL SOUTH UNIVERSITY   (China)

^q NANCHANG UNIVERSITY   (China)

^r Military General Hospital of Kunming   (China)

^s FUDAN UNIVERSITY   (China)

^t PEKING UNIVERSITY   (China)

^u DALIAN MEDICAL UNIVERSITY   (China)

^v ZHEJIANG UNIVERSITY   (China)

^w THIRD MILITARY MEDICAL UNIVERSITY   (China)

^x BEIJING HOSPITAL   (China)

^y WUHAN UNIVERSITY   (China)

more..

Author keywords

Clinical study; Levofloxacin; Lower respiratory tract infection; Urinary tract infection

Indexed keywords

LEVOFLOXACIN;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHINA; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; ERADICATION THERAPY; ESCHERICHIA COLI; FEMALE; FRACTURE; HAEMOPHILUS INFLUENZAE; HUMAN; INSOMNIA; LABORATORY TEST; LEUKOCYTE COUNT; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; LUNG TUMOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PLEURISY; PNEUMONIA; SIDE EFFECT; SOFT TISSUE INJURY; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 70350508580     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-009-0713-9     Document Type: Article

References (21)

1. D. Felmingham C. Feldman W. Hryniewicz K. Klugman S. Kohno D.E. Low, et al. 2002 Surveillance of resistance in bacteria causing community-acquired respiratory tract infections Clin Microbiol Infect 8 Suppl.2 12 42 10.1046/j.1469-0691.8.s.2.5.x 12427206 (Pubitemid 35203498)
2. P.C. Appelbaum 1992 Antimicrobial resistance in Streptococcus pneumoniae: an overview Clin Infect Dis 15 77 83 1:STN:280:DyaK38zhsVamug%3D%3D 1617076
3. Y.N. Liu M.J. Chen T.M. Zhao H. Wang R. Wang Q.F. Liu, et al. 2006 A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China Chin J Tuberc Respir Dis 29 3 8 1:CAS:528:DC%2BD2sXotl2itr8%3D
4. J.A. Karlowsky C. Thornsberry M.E. Jones A.T. Evangelista I.A. Critchley D.F. Sahm 2003 TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST surveillance program (1998-2002) Clin Infect Dis 36 963 970 10.1086/374052 12684907 (Pubitemid 36513279)
5. K. Suzuki T. Nishimura S. Baba 2003 Current status of bacterial resistance in the otolaryngology field: results from the second nationwide survey in Japan J Infect Chemother 9 46 52 10.1007/s10156-002-0209-3 12673407 (Pubitemid 36504370)
6. K. Yamaguchi A. Ohno Levofloxacin Surveillance Group 2005 Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002 Diagn Microbiol Infect Dis 52 135 143 10.1016/j.diagmicrobio.2005.02.009 1:CAS:528:DC%2BD2MXlt1Whs7o%3D 15964502 (Pubitemid 40826940)
7. Y.Y. Zhang D.M. Zhu F.P. Hu S. Wu F. Wang 2006 Changes of antimicrobial resistance among clinical isolates of Escherichia coli in Shanghai 1990-2004 Zhanghua Yi Xue Za Zhi 86 12 16 1:CAS:528:DC%2BD2sXktFKlsb8%3D (Pubitemid 43125202)
8. Chen HZ. Practice of internal medicine (in Chinese). In: Shanghai Medical College, Fudan University, editor. 11th ed. Beijing: People's Medical Publishing House; 2001. p. 1548-1551; p. 1566-8.
9. Wang F, Zhang YY. Practice of anti-infective therapy (in Chinese). In: Shanghai Medical College, Fudan University, editor. Beijing: People's Medical Publishing House; 2004. p. 464-471.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement, 2006, M100-S16. Bethesda: CLSI; 2006.
11. Guideline for clinical studies on antibiotics, issued by the Chinese Ministry of Health 1993 (in Chinese). Beijing: Chinese Ministry of Health; 1993.
12. M.K. Lacy W. Lu X. Xu P.R. Tessier D.P. Nicolau R. Quintiliani, et al. 1999 Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob Agents Chemother 43 672 677 1:CAS:528:DyaK1MXhsF2hu7w%3D 10049286 (Pubitemid 29109538)
13. D. Andes W.A. Craig 2002 Animal model pharmacokinetics and pharmacodynamics: a critical review Int J Antimicrob Agents 19 261 268 10.1016/S0924-8579(02)00022-5 1:CAS:528:DC%2BD38XjtVeis7c%3D 11978497 (Pubitemid 34308974)
14. W.A. Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 10 10.1086/516284 1:CAS:528:DyaK1cXltVaqtw%3D%3D 9455502
15. W.A. Craig 2001 Does the dose matter? Clin Infect Dis 33 Suppl3 233 237 10.1086/321854 (Pubitemid 32835797)
16. K.J. Madaras-Kelly T.A. Demasters 2000 In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae Diagn Microbiol Infect Dis 37 253 260 10.1016/S0732-8893(00)00147-4 1:CAS:528:DC%2BD3cXmtF2qs7w%3D 10974576 (Pubitemid 30676139)
17. S.L. Preston G.L. Drusano A.L. Berman C.L. Fowler A.T. Chow B. Dornseif, et al. 1998 Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials JAMA 279 125 129 10.1001/jama.279.2.125 1:CAS:528:DyaK1cXmvFGksg%3D%3D 9440662 (Pubitemid 28068302)
18. J.M. Blondeau X. Zhao G. Hansen K. Drlica 2001 Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 433 438 10.1128/AAC.45.2.433-438.2001 1:CAS:528:DC%2BD3MXmsVGmug%3D%3D 11158737 (Pubitemid 32105277)
19. J. Zhang J.C. Yu Y.G. Shi L. Zhou X.Y. Ye D.M. Zhu, et al. 2005 Study of pharmacokinetics/pharmacodynamics of levofloxacin Zhanghua Yi Xue Za Zhi 85 1926 1932 1:CAS:528:DC%2BD28Xlt1ajsb8%3D
20. Wang F, Zhu DM, Wang YQ. Survey of bacterial resistance to norfloxacin. Fourth International symposium on new quinolones. Munich, Germany, August 27-29, 1992; p. 19 (abstract no. 15).
21. F. Wang D.M. Zhu F.P. Hu F.Y. Ruan Y.X. Ni J.Y. Sun, et al. 2008 CHINET 2007 surveillance of bacterial resistance in China Chin J Infect Chemother 8 325 333 1:CAS:528:DC%2BD1cXhsVyntbzI